Koers Bausch Health Companies Inc Nyse
Aandelen
CA91911K1021
Farmaceutische producten
Omzet 2024 * | 9,39 mld. 8,79 mld. | Omzet 2025 * | 9,64 mld. 9,02 mld. | Marktkapitalisatie | 3,21 mld. 3,01 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 336 mln. 315 mln. | Nettowinst (verlies) 2025 * | 384 mln. 359 mln. | EV/omzet 2024 * | 0,34 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,33 x |
K/w-verhouding 2024 * |
13,3
x | K/w-verhouding 2025 * |
8,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,66% |
Recentste transcriptie over Bausch Health Companies Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Appio
CEO | Chief Executive Officer | 61 | - |
John Barresi
DFI | Director of Finance/CFO | 51 | 24-05-22 |
Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Power
BRD | Director/Board Member | 67 | 01-08-08 |
John Paulson
CHM | Chairman | 68 | 01-06-17 |
Steven Miller
BRD | Director/Board Member | 35 | 17-03-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,47% | 704 mld. | |
+28,59% | 577 mld. | |
-4,20% | 348 mld. | |
+18,57% | 327 mld. | |
+4,81% | 288 mld. | |
+14,64% | 234 mld. | |
+4,93% | 198 mld. | |
-9,78% | 194 mld. | |
-4,31% | 147 mld. |